Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease‐informed machine‐learning
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Introduction: Developing cross‐validated multi‐biomarker models for the prediction of the rate of cognitive decline in Alzheimer's disease (AD) is a critical yet unmet clinical challenge. Methods: We applied support vector regression to AD biomarkers derived from cerebrospinal fluid, structural magnetic resonance imaging (MRI), amyloid‐PET and fluorodeoxyglucose positron‐emission tomography (FDG‐PET) to predict rates of cognitive decline. Prediction models were trained in autosomal‐dominant Alzheimer's disease (ADAD, n = 121) and subsequently cross‐validated in sporadic prodromal AD (n = 216). The sample size needed to detect treatment effects when using model‐based risk enrichment was estimated. Results: A model combining all biomarker modalities and established in ADAD predicted the 4‐year rate of decline in global cognition (R 2 = 24%) and memory (R 2 = 25%) in sporadic AD. Model‐based risk‐enrichment reduced the sample size required for detecting simulated intervention effects by 50%–75%. Discussion: Our independently validated machine‐learning model predicted cognitive decline in sporadic prodromal AD and may substantially reduce sample size needed in clinical trials in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“27,42 The most predictive features in amyloid-PET included almost the entire neocortex, sparing primary sensorimotor, and medial temporal regions that develop amyloid very late in AD.”
Self-citationPerformance evaluation of classification algorithms by k-fold and leave-one-out cross validation
Wong, T.-T. (2015) · Pattern Recognition · doi:10.1016/j.patcog.2015.03.009 · Cited by 1,562
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Machine Learning Approaches for Clinical Psychology and Psychiatry
Dwyer, D. B., Falkai, P., & Koutsouleris, N. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045037 · Cited by 966 · cited 1×
“34,35 In DIAN, we applied SVR to the neuroimaging/biomarker values and randomly divided into 10 subsamples (inner CV1-folds).”
Self-citationAlzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697 · cited 1×
“27,42 The most predictive features in amyloid-PET included almost the entire neocortex, sparing primary sensorimotor, and medial temporal regions that develop amyloid very late in AD.”
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · cited 1×
“28,41 Importantly, theemergenceofcognitivesymptomsinADADisdrivenbyADpathol-ogy rather than age-related comorbidities, and thus, provides a good model for AD-related cognitive decline.”
Self-citationOn the path to 2025: understanding the Alzheimer’s disease continuum
Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0283-5 · Cited by 556
Self-citationSymptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis
Ryman, D. C., Acosta-Baena, N., Aisen, P. S., Bird, T., Danek, A., Fox, N. C., Goate, A., Frommelt, P., Ghetti, B., Langbaum, J. B. S., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000596 · Cited by 502
Self-citationIn vivo staging of regional amyloid deposition
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004643 · Cited by 440
Self-citationRegional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317918110 · Cited by 391
Self-citationBaykara, E., Gesierich, B., Adam, R., Tuladhar, A. M., Biesbroek, J. M., Koek, H. L., Ropele, S., Jouvent, E., Initiative, A. D. N., Chabriat, H., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24758 · Cited by 386
Self-citationBittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.009 · Cited by 374
Koutsouleris, N., Kambeitz-Ilankovic, L., Ruhrmann, S., Rosen, M., Ruef, A., Dwyer, D. B., Paolini, M., Chisholm, K., Kambeitz, J., Haidl, T., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.2165 · Cited by 341
Self-citationLongitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314 · cited 2×
“47 However, several caveats should be considered when interpreting Third, we trained the model on EYO in ADAD, which is only a cross-sectional proxy of future cognitive decline.”
Self-citationInfluence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease
Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Morris, J. C., & Hassenstab, J. J. (2018) · Neurology · doi:10.1212/wnl.0000000000006075 · Cited by 290
Self-citationRoberts, R. O., Aakre, J. A., Kremers, W. K., Vassilaki, M., Knopman, D. S., Mielke, M. M., Alhurani, R., Geda, Y. E., Machulda, M. M., Coloma, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0629 · Cited by 223 · cited 1×
“Importantly, in sporadic AD, we found that biomarker-based risk enrichment led to drastically lower sample sizes required to detect intervention effects with cognitive decline as an endpoint.”
Magnetic resonance imaging in Alzheimer’s disease neuroimaging initiative 2
Jack, C. R., Barnes, J., Bernstein, M. A., Borowski, B. J., Brewer, J., Clegg, S., Dale, A. M., Carmichael, O., Ching, C., DeCarli, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.002 · Cited by 220
Self-citationQuiroz, Y. T., Sperling, R. A., Norton, D. J., Baena, A., Arboleda-Velasquez, J. F., Cosio, D., Schultz, A., Lapoint, M., Guzman-Velez, E., Miller, J. B., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4907 · Cited by 186 · cited 1×
“43,44 Further, predictive regions included posterior parietal and medial temporal regions for MRI and posterior parietal and lateral frontal regions for FDG-PET, that is, AD-typical predilection sites.”
Bhagwat, N., Viviano, J. D., Voineskos, A. N., Chakravarty, M. M., & Initiative, A. D. N. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006376 · Cited by 157 · cited 2×
“Previous studies evaluating biomarker combinations 9,12 or machine learning demonstrated that biomarker combinations can enhance the accuracy of predicting cognitive decline or conversion to dementia.”
Ringman, J. M., Monsell, S., Ng, D. W., Zhou, Y., Nguyen, A., Coppola, G., Van Berlo, V., Mendez, M. F., Tung, S., Weintraub, S., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv028 · Cited by 99 · cited 1×
“39 This allowed extracting AD-specific brain changes that occur early in the disease course.”
Research works printed but not linked: 28
- 10.1186/alzrt95 · DOI
- 10.3389/fnagi.2013.00055 · DOI · Paper page
- 10.1093/brain/awq277 · DOI · Paper page
- 10.1016/j.neuroimage.2010.10.081 · DOI · Paper page
- 10.1212/01.wnl.0000286944.22262.ff · DOI · Paper page
- Frolich L, 2017, Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia, Alzheimers Res Ther, 9, 84, 10.1186/s13195-017-0301-7 · DOI · Paper page
- 10.1001/jamaneurol.2017.0892 · DOI · Paper page
- 10.1002/ana.23650 · DOI · Paper page
- 10.3233/JAD-2012-121408 · DOI · Paper page
- 10.1001/jamaneurol.2016.0194 · DOI · Paper page
- 10.1001/jamaneurol.2018.0894 · DOI · Paper page
- 10.1016/j.neuroimage.2010.11.004 · DOI · Paper page
- 10.1371/journal.pone.0077949 · DOI · Paper page
- 10.1016/j.bbr.2018.02.017 · DOI · Paper page
- 10.1093/brain/awy093 · DOI · Paper page
- 10.2214/AJR.18.20224 · DOI · Paper page
- 10.1016/j.dadm.2015.01.006 · DOI · Paper page
- 10.1016/j.neuroimage.2009.11.046 · DOI · Paper page
- 10.2967/jnumed.112.109009 · DOI · Paper page
- 10.1016/j.jalz.2015.05.001 · DOI · Paper page
- 10.1002/cem.1225 · DOI · Paper page
- 10.1007/s11682-012-9186-z · DOI · Paper page
- 10.1007/s00415-012-6481-y · DOI · Paper page
- Day GS, 2016, Phenotypic similarities between late‐onset autosomal dominant and sporadic Alzheimer disease: a single‐family case‐control study, JAMA Neurol, 73, 1125, 10.1001/jamaneurol.2016.1236 · DOI
- Ansart M, 2019, Reduction of recruitment costs in preclinical AD trials: validation of automatic pre‐screening algorithm for brain amyloidosis, Stat Methods Med Res
- 10.1016/j.trci.2017.04.005 · DOI · Paper page
- 10.1016/j.nicl.2018.08.019 · DOI · Paper page
- 10.1212/WNL.0000000000004860 · DOI · Paper page
Cited by
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12422 · Cited by 184
Self-citationDissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151
Algorithmic fairness of machine learning models for Alzheimer disease progression
Yuan, C., Linn, K. A., & Hubbard, R. A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.42203 · Cited by 49
Mirkin, S., & Albensi, B. C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1094233 · Cited by 46
Heneghan, A., Deng, F., Wells, K., Ritchie, K., Muniz-Terrera, G., Ritchie, C. W., Lawlor, B., & Naci, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220267 · Cited by 18
Metadata
- Authors
- Franzmeier, N., Koutsouleris, N., Benzinger, T., Goate, A., Karch, C. M., Fagan, A. M., McDade, E., Duering, M., Dichgans, M., Levin, J., Gordon, B. A., Lim, Y. Y., Masters, C. L., Rossor, M., Fox, N. C., O'Connor, A., Chhatwal, J., Salloway, S., Danek, A., Hassenstab, J., Schofield, P. R., Morris, J. C., Bateman, R. J., (ADNI), T. A. D. N. I., the Dominantly Inherited Alzheimer Network (DIAN), & Ewers, M.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2020-02-11
- Volume
- 16
- Issue
- 3
- Pages
- 501-511
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W3005937372
- Cited by
- 73
- References
- 22
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.